QuintilesIMS leading Big Pharma firms in oncology collaboration

According to WHO, cancer is a leading cause of death and morbidity in Europe with more than 1.7 million deaths and three million new cases each year. (Image: iStock/Toa55)

The new collaborative initiative will be led by QuintilesIMS, with founding partners including Bristol-Myers Squibb, Eli Lilly and Company, Merck KGaA, and Pfizer.

While the renewals are a topic of concern for investors, analysts believe both CROs will see a re-up. (Image: iStock/shironosov)

Will Pfizer renew with Icon, Parexel? Analyst says yes

IBM Research Data Scientist Eric Clark explores wearable technologies that could help monitor and analyze biological data from study subjects on Thursday, April 7, 2016 at IBM's T. J. Watson Research Center in Yorktown, NY. (Image: IBM)

Pfizer and IBM join forces to develop remote monitoring solutions

Image: iStock

Pfizer hits up four biotechs in $46m R&D collaboration strategy

Catalent will make Nexium for Pfizer from its Kentucky site

Pfizer selects Catalent to make Nexium from expanded Kentucky plant

CMOs will need to be giant, or small and specialised, to survive the coming years, says an M&A expert

Pfizer-Allergan deal: what next for contract manufacturers?

Photo - iStock/Tashatuvango

Megamerger Pfall-out? $160bn Pfizer-Allergan deal to hit CROs in short-term, analysts

Roche: Small molecule exit will lead to outsourcing opportunities

Roche: Small molecule exit will lead to outsourcing opportunities

Parexel had a bookings cancellation rate of 5.7%, equating to $305m worth of business, for its first quarter FY2016

'Highest ever' cancellation rate impairs Parexel's Q1 FY16 results

Novartis JV helps virtual trial CRO to $6.5m fundraising round

Novartis joint venture helps virtual trial CRO to $6.5m fundraising round

More Pfizer